Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Repare Therapeutics ( (RPTX) ) is now available.
On July 15, 2025, Repare Therapeutics entered into an exclusive worldwide license agreement with Debiopharm International for the development and commercialization of lunresertib, a PKMYT1 inhibitor. The agreement grants Debiopharm rights to develop and market products containing lunresertib, either alone or in combination with Debio 0123. Repare will receive a $10 million upfront payment and potentially up to $257 million in milestone payments, along with royalties on global sales. This collaboration builds on their previous partnership and allows Debiopharm to assume responsibility for the ongoing MYTHIC clinical trial. The deal supports Repare’s focus on advancing its clinical priorities, particularly the ongoing Phase 1 trials for RP-3467 and RP-1664, with data expected in the latter half of 2025.
The most recent analyst rating on (RPTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.
Spark’s Take on RPTX Stock
According to Spark, TipRanks’ AI Analyst, RPTX is a Neutral.
Repare Therapeutics’ overall score is driven by significant financial challenges but buoyed by positive technical analysis and corporate events. The strategic out-licensing deal with DCx Biotherapeutics is a highlight, providing financial benefits and strategic focus. However, the valuation remains a concern due to ongoing losses and a negative P/E ratio.
To see Spark’s full report on RPTX stock, click here.
More about Repare Therapeutics
Repare Therapeutics is a clinical-stage precision oncology company that focuses on developing novel therapeutics using a proprietary synthetic lethality approach. The company is engaged in creating highly targeted cancer therapies aimed at genomic instability, including DNA damage repair. Its clinical-stage pipeline features RP-3467, a Phase 1 Polθ ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor.
Average Trading Volume: 260,751
Technical Sentiment Signal: Sell
Current Market Cap: $67.34M
Learn more about RPTX stock on TipRanks’ Stock Analysis page.